Drugs that contain Fingolimod Hydrochloride

1. Drug name - GILENYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324283 NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol Mar, 2026

(3 years from now)

US8324283

(Pediatric)

NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol Sep, 2026

(3 years from now)

US9187405 NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis Jun, 2027

(4 years from now)

US10543179 NOVARTIS Dosage regimen of an S1P receptor modulator Dec, 2027

(5 years from now)

US9187405

(Pediatric)

NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis Dec, 2027

(5 years from now)

US9592208 NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Mar, 2032

(9 years from now)

US9592208

(Pediatric)

NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Sep, 2032

(9 years from now)

Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE CAPSULE;ORAL Prescription
EQ 0.5MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.